{
    "clinical_study": {
        "@rank": "102576", 
        "arm_group": {
            "arm_group_label": "Mifepristone", 
            "arm_group_type": "Experimental", 
            "description": "Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether mifepristone is an effective treatment for\n      hyperglycemia due to mild hypercortisolism.\n\n        -  To test the hypothesis that GR blockade with mifepristone will decrease the severity of\n           metabolic syndrome features as measured by waist circumference, lipid profile, body\n           mass index, blood pressure and insulin resistance, measured by HOMA-IR score.\n\n        -  To test the hypothesis that GR blockade with mifepristone will improve QoL, depression\n           and anxiety scores, measured by validated assessments, in patients with mild\n           hypercortisolism."
        }, 
        "brief_title": "Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Mild Hypercortisolism", 
        "condition_browse": {
            "mesh_term": [
                "Adrenocortical Hyperfunction", 
                "Cushing Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  >18 years of age\n\n          -  Incidentally noted adrenal nodule <4 cm with benign imaging characteristics\n\n          -  Evidence of mild hypercortisolism\n\n          -  Evidence of diabetes or abnormal glucose tolerance\n\n        Exclusion Criteria:\n\n          -  contraindication to mifepristone\n\n          -  Indication for unilateral adrenalectomy\n\n          -  Evidence of other adrenal hormone hypersecretion\n\n          -  lactating mothers\n\n          -  women of childbearing age unwilling to use an effective, nonhormonal form of\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990560", 
            "org_study_id": "GCO 13-1061"
        }, 
        "intervention": {
            "arm_group_label": "Mifepristone", 
            "description": "All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period", 
            "intervention_name": "Mifepristone", 
            "intervention_type": "Drug", 
            "other_name": "Korlym"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glucocorticoids", 
                "Mifepristone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "mild hypercortisolism", 
            "Subclinical Cushing's Syndrome", 
            "Preclinical Cushing's Syndrome"
        ], 
        "lastchanged_date": "November 15, 2013", 
        "location": {
            "contact": {
                "email": "Gillian.m.goddard@mssm.edu", 
                "last_name": "Gillian Goddard, MD", 
                "phone": "212-241-1500"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Icahn School of Medicine at Mount Sinai"
            }, 
            "investigator": {
                "last_name": "Alice C Levine, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism", 
        "overall_contact": {
            "email": "Gillian.m.goddard@mssm.edu", 
            "last_name": "Gillian Goddard, MD", 
            "phone": "212-241-1500"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Alice C Levine, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Improvement in hyperglycemia - fasting glucose, HbA1c, HOMA-IR (a validated assessment of insulin resistance, HOMA-IR = (glucose md/dl x insulin mg/dl)/405)", 
            "measure": "hyperglycemia", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "10732270", 
                "citation": "Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000 Mar;29(1):159-85, x. Review."
            }, 
            {
                "PMID": "15082524", 
                "citation": "Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004 Apr;25(2):309-40. Review."
            }, 
            {
                "PMID": "12414841", 
                "citation": "Tauchmanov\u00e0 L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002 Nov;87(11):4872-8."
            }, 
            {
                "PMID": "11889151", 
                "citation": "Terzolo M, Pia A, Al\u00ec A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002 Mar;87(3):998-1003."
            }, 
            {
                "PMID": "11701696", 
                "citation": "Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab. 2001 Nov;86(11):5301-6."
            }, 
            {
                "PMID": "23345100", 
                "citation": "Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab. 2013 Feb;98(2):425-38. doi: 10.1210/jc.2012-3126. Epub 2013 Jan 23. Review."
            }, 
            {
                "PMID": "23393167", 
                "citation": "Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab. 2013 Mar;98(3):1022-30. doi: 10.1210/jc.2012-2893. Epub 2013 Feb 7."
            }, 
            {
                "PMID": "23577182", 
                "citation": "Debono M, Chadarevian R, Eastell R, Ross RJ, Newell-Price J. Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study. PLoS One. 2013;8(4):e60984. doi: 10.1371/journal.pone.0060984. Epub 2013 Apr 5."
            }, 
            {
                "PMID": "18334580", 
                "citation": "Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008 May;93(5):1526-40. Epub 2008 Mar 11."
            }, 
            {
                "PMID": "10702749", 
                "citation": "Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48."
            }, 
            {
                "PMID": "14749739", 
                "citation": "Parker BA, Sturm K, MacIntosh CG, Feinle C, Horowitz M, Chapman IM. Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur J Clin Nutr. 2004 Feb;58(2):212-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990560"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mount Sinai School of Medicine", 
            "investigator_full_name": "Alice C. Levine", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Improvement in metabolic syndrome - outcomes include cortisol, fasting lipid profile, weight, BMI (kg/m2), waist circumference (in centimeters), and blood pressure", 
                "measure": "Metabolic Syndrome", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Improvement in Quality of Life - completion of 3 validated QoL questionnaires (Cushing's Quality of Life questionnaire (CushingQoL), Nottingham Health Profile (NHP), and Hospital Anxiety and Depression Scale (HADS)), and the visual analogue scale (VAS) to quantify appetite. Patients will also complete the Beck Depression Inventory and the State Trait Anxiety Inventory (STAI).", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Mount Sinai School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}